Year-End Report 2018

The Board of Directors and the CEO reports the following for the fiscal year 2018. Unless otherwise stated, all amounts are reported in integers SEK (SEK). Data in parentheses refer to the previous year.

Summary of the year-end report

TWELVE MONTHS (January – December 2018) 

• The company’s sales amounted to 41 (0) KSEK. 
• Other operating income amounted to 17 (153) KSEK. 
• Capitalised development expenses amounted to 427 (694) KSEK. 
• Costs amounted to 9,795 (8,995) KSEK. 
• Result before and after tax amounted to -9,311 (-8,148) KSEK. 
• Result per share amounted to -0.94 (-0.94) SEK. 
• Cash and cash equivalents at the end of the period amounted to 12,889 KSEK. 
• The board and the CEO propose that no dividend be paid for the financial year 2018-01-01 – 2018-12-31. 

FOURTH QUARTER (October – December 2018) 

• The company’s sales amounted to 41 (0) KSEK. 
• Other operating income amounted to 0 (0) KSEK. 
• Capitalised development expenses amounted to 0 (172) KSEK. 
• Costs amounted to 2,747 (3,110) KSEK. 
• Result before and after tax amounted to 2,706 (2,938) KSEK. 
• Result per share amounted to 0,26 (-0,33) KSEK. 

Results in brief 

CEO Karin Bryder summarises the quarter 

In the beginning of October, we were able to finally launch the first Arcamea product Efemia Bladder Support via arcamea.se after a strong finish of the development phase in 2018. Thanks to our strategy to initiate discussions early with potential distribution partners, we were able to announce  that  an  evaluation  of the  product  was initiated in Germany during the quarter. The first agreement, with Sweden’s largest pharmacy chain Apoteket 

AB, was then presented after the end of the period. We were also able to initiate a post-launch study during the quarter with Aller media, and the company received notification on an additional patent approval in the USA.